138 related articles for article (PubMed ID: 19429408)
1. Pharmacokinetic modeling of perfluorooctanoic acid during gestation and lactation in the mouse.
Rodriguez CE; Setzer RW; Barton HA
Reprod Toxicol; 2009 Jun; 27(3-4):373-386. PubMed ID: 19429408
[TBL] [Abstract][Full Text] [Related]
2. Analysis of PFOA in dosed CD1 mice. Part 1. Methods development for the analysis of tissues and fluids from pregnant and lactating mice and their pups.
Reiner JL; Nakayama SF; Delinsky AD; Stanko JP; Fenton SE; Lindstrom AB; Strynar MJ
Reprod Toxicol; 2009 Jun; 27(3-4):360-364. PubMed ID: 19028561
[TBL] [Abstract][Full Text] [Related]
3. Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures.
Wolf CJ; Fenton SE; Schmid JE; Calafat AM; Kuklenyik Z; Bryant XA; Thibodeaux J; Das KP; White SS; Lau CS; Abbott BD
Toxicol Sci; 2007 Feb; 95(2):462-73. PubMed ID: 17098816
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of fetal and child PFOA dosimetry in the derivation of health-based toxicity values.
Kieskamp KK; Worley RR; McLanahan ED; Verner MA
Environ Int; 2018 Feb; 111():260-267. PubMed ID: 29325971
[TBL] [Abstract][Full Text] [Related]
5. Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages.
Loccisano AE; Longnecker MP; Campbell JL; Andersen ME; Clewell HJ
J Toxicol Environ Health A; 2013; 76(1):25-57. PubMed ID: 23151209
[TBL] [Abstract][Full Text] [Related]
6. Effects of perfluorooctanoic acid (PFOA) on expression of peroxisome proliferator-activated receptors (PPAR) and nuclear receptor-regulated genes in fetal and postnatal CD-1 mouse tissues.
Abbott BD; Wood CR; Watkins AM; Tatum-Gibbs K; Das KP; Lau C
Reprod Toxicol; 2012 Jul; 33(4):491-505. PubMed ID: 22154759
[TBL] [Abstract][Full Text] [Related]
7. Prenatal perfluorooctanoic acid exposure in CD-1 mice: low-dose developmental effects and internal dosimetry.
Macon MB; Villanueva LR; Tatum-Gibbs K; Zehr RD; Strynar MJ; Stanko JP; White SS; Helfant L; Fenton SE
Toxicol Sci; 2011 Jul; 122(1):134-45. PubMed ID: 21482639
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model.
Loccisano AE; Campbell JL; Butenhoff JL; Andersen ME; Clewell HJ
Reprod Toxicol; 2012 Jul; 33(4):468-490. PubMed ID: 21872655
[TBL] [Abstract][Full Text] [Related]
9. Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model.
Loccisano AE; Campbell JL; Butenhoff JL; Andersen ME; Clewell HJ
Reprod Toxicol; 2012 Jul; 33(4):452-467. PubMed ID: 21565266
[TBL] [Abstract][Full Text] [Related]
10. Analysis of PFOA in dosed CD-1 mice. Part 2. Disposition of PFOA in tissues and fluids from pregnant and lactating mice and their pups.
Fenton SE; Reiner JL; Nakayama SF; Delinsky AD; Stanko JP; Hines EP; White SS; Lindstrom AB; Strynar MJ; Petropoulou SE
Reprod Toxicol; 2009 Jun; 27(3-4):365-372. PubMed ID: 19429407
[TBL] [Abstract][Full Text] [Related]
11. Modeling single and repeated dose pharmacokinetics of PFOA in mice.
Lou I; Wambaugh JF; Lau C; Hanson RG; Lindstrom AB; Strynar MJ; Zehr RD; Setzer RW; Barton HA
Toxicol Sci; 2009 Feb; 107(2):331-41. PubMed ID: 19005225
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic modeling of human exposure to perfluorooctanoic acid suggests historical non drinking-water exposures are important for predicting current serum concentrations.
Worley RR; Yang X; Fisher J
Toxicol Appl Pharmacol; 2017 Sep; 330():9-21. PubMed ID: 28684146
[TBL] [Abstract][Full Text] [Related]
13. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha.
Abbott BD; Wolf CJ; Schmid JE; Das KP; Zehr RD; Helfant L; Nakayama S; Lindstrom AB; Strynar MJ; Lau C
Toxicol Sci; 2007 Aug; 98(2):571-81. PubMed ID: 17488742
[TBL] [Abstract][Full Text] [Related]
14. Gestational PFOA exposure of mice is associated with altered mammary gland development in dams and female offspring.
White SS; Calafat AM; Kuklenyik Z; Villanueva L; Zehr RD; Helfant L; Strynar MJ; Lindstrom AB; Thibodeaux JR; Wood C; Fenton SE
Toxicol Sci; 2007 Mar; 96(1):133-44. PubMed ID: 17132714
[TBL] [Abstract][Full Text] [Related]
15. Comparing models for perfluorooctanoic acid pharmacokinetics using Bayesian analysis.
Wambaugh JF; Barton HA; Setzer RW
J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):683-712. PubMed ID: 19130186
[TBL] [Abstract][Full Text] [Related]
16. Perfluorooctanoic acid and perfluorononanoic acid in fetal and neonatal mice following in utero exposure to 8-2 fluorotelomer alcohol.
Henderson WM; Smith MA
Toxicol Sci; 2007 Feb; 95(2):452-61. PubMed ID: 17093205
[TBL] [Abstract][Full Text] [Related]
17. The mammary gland is a sensitive pubertal target in CD-1 and C57Bl/6 mice following perinatal perfluorooctanoic acid (PFOA) exposure.
Tucker DK; Macon MB; Strynar MJ; Dagnino S; Andersen E; Fenton SE
Reprod Toxicol; 2015 Jul; 54():26-36. PubMed ID: 25499722
[TBL] [Abstract][Full Text] [Related]
18. Perflurooctanoic acid induces developmental cardiotoxicity in chicken embryos and hatchlings.
Jiang Q; Lust RM; Strynar MJ; Dagnino S; DeWitt JC
Toxicology; 2012 Mar; 293(1-3):97-106. PubMed ID: 22273728
[TBL] [Abstract][Full Text] [Related]
19. Use of simple pharmacokinetic modeling to characterize exposure of Australians to perfluorooctanoic acid and perfluorooctane sulfonic acid.
Thompson J; Lorber M; Toms LL; Kato K; Calafat AM; Mueller JF
Environ Int; 2010 May; 36(4):390-397. PubMed ID: 20236705
[TBL] [Abstract][Full Text] [Related]
20. Does developmental exposure to perflurooctanoic acid (PFOA) induce immunopathologies commonly observed in neurodevelopmental disorders?
Hu Q; Franklin JN; Bryan I; Morris E; Wood A; DeWitt JC
Neurotoxicology; 2012 Dec; 33(6):1491-1498. PubMed ID: 23137609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
